Ryan J. Sullivan

44.4k total citations · 8 hit papers
395 papers, 13.4k citations indexed

About

Ryan J. Sullivan is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ryan J. Sullivan has authored 395 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 297 papers in Oncology, 165 papers in Molecular Biology and 75 papers in Immunology. Recurrent topics in Ryan J. Sullivan's work include Cancer Immunotherapy and Biomarkers (175 papers), Melanoma and MAPK Pathways (122 papers) and CAR-T cell therapy research (104 papers). Ryan J. Sullivan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (175 papers), Melanoma and MAPK Pathways (122 papers) and CAR-T cell therapy research (104 papers). Ryan J. Sullivan collaborates with scholars based in United States, Australia and Germany. Ryan J. Sullivan's co-authors include Keith T. Flaherty, Donald P. Lawrence, Douglas B. Johnson, Kerry L. Reynolds, Justine V. Cohen, Jeffrey S. Weber, Alexander M. Menzies, Alexander T. Faje, Riley Fadden and F. Stephen Hodi and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Ryan J. Sullivan

369 papers receiving 13.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

2018 1.1k citations Justine V. Cohen, Kerry L. Reynolds et al. profile →
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2016 604 citations Alexander M. Menzies, Douglas B. Johnson et al. Annals of Oncology profile →
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

2018 456 citations Dennie T. Frederick, Ryan J. Sullivan et al. profile →
Clusters of circulating tumor cells traverse capillary-sized vessels

2016 366 citations Ryan J. Sullivan et al. profile →
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

2020 356 citations Zsófia D. Drobni, Daniel A. Zlotoff et al. profile →
High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma

2018 348 citations Donald P. Lawrence, Keith T. Flaherty et al. Cancer profile →
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

2020 307 citations Tatyana Sharova, F. Stephen Hodi et al. profile →
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

2021 187 citations Ryan J. Sullivan, Jeffrey S. Weber profile →

Peers

Countries citing papers authored by Ryan J. Sullivan

Since Specialization

Citations

This map shows the geographic impact of Ryan J. Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan J. Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan J. Sullivan more than expected).

Fields of papers citing papers by Ryan J. Sullivan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan J. Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan J. Sullivan. The network helps show where Ryan J. Sullivan may publish in the future.

Co-authorship network of co-authors of Ryan J. Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan J. Sullivan. A scholar is included among the top collaborators of Ryan J. Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan J. Sullivan. Ryan J. Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma 2024 ·Journal for ImmunoTherapy of Cancer ·Yu Jen Jan, Cho‐Han Chiang, (unknown), Aleigha Lawless, Kerry L. Reynolds, Ryan J. Sullivan	1
2	Targeted Therapy Innovations for Melanoma 2024 ·Hematology/Oncology Clinics of North America ·(unknown), Keith T. Flaherty, Ryan J. Sullivan	4
3	Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma. 2024 ·Journal of Clinical Oncology ·Jeffrey S. Weber, Amrutesh S. Puranik, (unknown), (unknown), Judith D. Goldberg, Janice M. Mehnert, Xiaochun Li, Benjamin Levinson, Omid Hamid, Inderjit Mehmi, Mark B. Faries, F. Stephen Hodi, Elizabeth I. Buchbinder, Patrick A. Ott, (unknown), (unknown), (unknown), Ryan J. Sullivan	10
4	Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. 2023 ·Journal of Clinical Oncology ·Adnan Khattak, Jeffrey S. Weber, Tarek Meniawy, Matthew H. Taylor, George Ansstas, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, (unknown), Theresa Medina, Jennifer Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Elizabeth I. Buchbinder, Robert Meehan, Matteo S. Carlino, (unknown)	50
5	Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial 2023 ·Clinical Cancer Research ·David S. Hong, Michael A. Postow, Bartosz Chmielowski, Ryan J. Sullivan, Amita Patnaik, Ezra E.W. Cohen, Geoffrey I. Shapiro, Conor Steuer, Martin Gutierrez, (unknown), Robert Ilaria, Brenda O’Connell, Joanna Peng, (unknown), Nora Zizlsperger, Anthony W. Tolcher, Jedd D. Wolchok	48
6	Atrial and ventricular arrhythmias with immune checkpoint inhibitor therapy in patients without evidence of myocarditis 2023 ·European Heart Journal ·(unknown), Thiago Quinaglia, Zsófia D. Drobni, Jennifer E. Ho, Hannah Gilman, Daniel A. Zlotoff, Giselle Alexandra Suero‐Abreu, Leyre Zubiri, Ryan J. Sullivan, Kerry L. Reynolds, Tomas G. Neilan	3
7	Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma 2023 ·JAMA Network Open ·Rachel Goodman, Aleigha Lawless, Rachel Woodford, Faisal Fa’ak, (unknown), James R. Patrinely, Hui‐Ling Yeoh, Suthee Rapisuwon, Andrew Haydon, Iman Osman, Janice M. Mehnert, Georgina V. Long, Ryan J. Sullivan, Matteo S. Carlino, Alexander M. Menzies, Douglas B. Johnson	30
8	Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses 2023 ·Immunological Reviews ·Steven M. Blum, Sherin J. Rouhani, Ryan J. Sullivan	57
9	LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial 2023 ·Annals of Oncology ·Sophie Piperno‐Neumann, (unknown), Piotr Rutkowski, J.F. Baurain, Max Schlaak, Marcus O. Butler, Ryan J. Sullivan, Reinhard Dummer, (unknown), (unknown), (unknown), Sebastian Ochsenreither, Anthony M. Joshua, (unknown), Brendan D. Curti, (unknown), Omid Hamid, Linda Collins, Christopher P. Holland, Paul Nathan	0
10	The case for adjuvant BRAF‐targeted therapy versus adjuvant anti–PD‐1 therapy for patients with resected, high‐risk melanoma 2023 ·Cancer ·Meghan J. Mooradian, Ryan J. Sullivan	4
11	664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors 2023 ·Annals of Oncology ·Ryan B. Corcoran, T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes, Leanne G. Ahronian, Gianluca Mauri, Ju Tian, Joan S. Brugge, Dejan Juric, K. T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, U. Matulonis, (unknown), Geoffrey I. Shapiro	1
12	Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis 2023 ·Journal for ImmunoTherapy of Cancer ·Meghan E. Sise, Qiyu Wang, Harish Seethapathy, (unknown), (unknown), R. Neal Smith, Ivy A. Rosales, Robert B. Colvin, (unknown), Lynn D. Cornell, Sandra M. Herrmann, Riley Fadden, Ryan J. Sullivan, (unknown), Sara Barmettler, (unknown), Shruti Gupta, Alexandra–Chloé Villani, Kerry L. Reynolds, Jocelyn R. Farmer	23
13	Clinical and genomic correlates of imatinib response in melanomas with KIT alterations 2022 ·British Journal of Cancer ·(unknown), (unknown), Alexander Z. Wei, Fei Ye, (unknown), Matteo S. Carlino, Ryan J. Sullivan, Richard D. Carvajal, Alexander N. Shoushtari, Douglas B. Johnson	15
14	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort 2021 ·Journal for ImmunoTherapy of Cancer ·Xue Bai, Michelle Kim, Gyulnara G. Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley Fadden, Krista M. Rubin, Tatyana Sharova, Dennie T. Frederick, Keith T. Flaherty, Ryan J. Sullivan, Jun Guo, Genevieve M. Boland	8
15	Rejection of benign melanocytic nevi by nevus-resident CD4 ⁺ T cells 2021 ·Science Advances ·(unknown), (unknown), Seokjin Ham, (unknown), (unknown), Donald P. Lawrence, Justine V. Cohen, Keith T. Flaherty, James J. Moon, Christine G. Lian, Ryan J. Sullivan, Shadmehr Demehri	9
16	Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients 2019 ·Cancer Immunology Research ·Douglas B. Johnson, (unknown), Justine V. Cohen, (unknown), Alexandra M. Haugh, Daniel Wang, (unknown), (unknown), Kenneth L. Gage, Florian J. Fintelmann, Ryan J. Sullivan, Zeynep Eroglu, Richard G. Abramson	20
17	A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma 2017 ·Cancer Immunology Research ·Jeffrey S. Weber, Mario Sznol, Ryan J. Sullivan, Shauna Blackmon, Genevieve M. Boland, Harriet M. Kluger, Ruth Halaban, Antonietta Bacchiocchi, Paolo A. Ascierto, Mariaelena Capone, Carlos Oliveira, Krista Meyer, Julia Grigorieva, (unknown), Joanna Roder, Heinrich Röder	53
18	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance 2016 ·Cancer Discovery ·Miles A. Miller, Madeleine J. Oudin, Ryan J. Sullivan, Stephanie J. Wang, Aaron S. Meyer, Hyungsoon Im, Dennie T. Frederick, Jenny Tadros, Linda G. Griffith, Hakho Lee, Ralph Weissleder, Keith T. Flaherty, Frank B. Gertler, Douglas A. Lauffenburger	138
19	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies 2015 ·Cancer Immunology Research ·Douglas B. Johnson, Christine M. Lovly, Marisa Flavin, Katherine S. Panageas, Gregory D. Ayers, Zhiguo Zhao, Wade T. Iams, (unknown), (unknown), Charles R. Terry, Elizabeth Berry, A. John Iafrate, Ryan J. Sullivan, Richard D. Carvajal, Jeffrey A. Sosman	132
20	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition 2015 ·Clinical Cancer Research ·Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, René González, Jose Lutzky, Steven O’Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil H. Ramaiya, Anita Giobbie‐Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact